• 403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD

  • Sep 6 2023
  • Durée: 16 min
  • Podcast

403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • For this “ABCs of NMOSD” episode, Rebecca Whitney of SRNA was joined by Dr. Michael Levy. Dr. Levy gave an overview of I-CAN, a Phase 2 study of inebilizumab in children with aquaporin-4 positive neuromyelitis optica spectrum disorder or NMOSD. As one of the principal investigators for the study, he shared details about inclusion criteria and inebilizumab, brand name Uplizna™. Dr. Levy also discussed what someone can expect if they choose to participate in this trial, how participation would impact someone’s current treatment, and the timeline of this trial. Additional information is available here:

    https://wearesrna.org/clinical-studies-and-trials/study-of-inebilizumab-in-pediatric-subjects-with-neuromyelitis-optica-spectrum-disorder/ 

    https://clinicaltrials.gov/study/NCT05549258?term=NCT05549258&aggFilters=status:not%20rec&rank=1
    Voir plus Voir moins
Voir plus Voir moins

Ce que les auditeurs disent de 403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.